Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - B-Cell Lymphomas

May 29, 2019

Diagnosis and Treatment of Diffuse Large B-Cell Lymphomas (DLBCL)
DLBCL is now considered a heterogeneous group of distinct molecular subtypes characterized by substantially different clinical outcomes to standard chemoimmunotherapy.  New insights about the pathogenesis of DLBCL will eventually result in the development of more appropriately targeted therapies for the molecular subtypes of DLBCL. Accurate diagnosis with adequate immunophenotyping to identify the distinct molecular subtypes is the essential first step in the management of patients with DLBCL. Clinicians need to be educated about the recent advances that will lead to informed clinical decisions for individual patients and help clinicians incorporate these findings more effectively into their clinical management of patients with DLBCL.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the molecular heterogeneity of DLBCL and its implications in the management of patients with DLBCL.
  • Summarize the current options for the treatment of newly diagnosed DLBCL and discuss the evidence from clinical trials on the use of novel therapeutic strategies. 
  • Develop a treatment plan that integrates novel treatment options for the management of patients with relapsed/refractory DLBCL.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas
  • AstraZeneca
  • Bayer U.S. LLC
  • Celgene Corporation
  • Clovis Oncology
  • Eisai
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Lilly
  • Novartis
  • Taiho Oncology

This activity is supported by an independent educational grant from TESARO.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
04/09/2019
Course expires: 
07/21/2019
Event starts: 
05/29/2019 - 3:30pm
Event ends: 
05/29/2019 - 4:30pm
Cost:
$0.00
Parent activity set: 

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Jason T. Carter, PA-C, MHS, MPH, MA
Memorial Sloan Kettering Cancer Center

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Full disclosure of faculty relationships will be made prior to the activity.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-19-029-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Accreditation Period

Course opens: 
04/09/2019
Course expires: 
07/21/2019

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

This webinar will be presented live one time only on Wednesday, May 29, 2019, from 3:30 - 4:30 PM Eastern Daylight Time (EDT) (UTC -4).  To adjust for other time zones, click here.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing